Boehringer Ingelheim has entered a multi-year partnership with Tempus AI to progress its cancer therapy pipeline. The collaboration builds upon previous joint efforts, utilising AI and data to ...

This partnership aims to integrate Tempus’s extensive de-identified database and analytical platform with Boehringer Ingelheim’s oncology pipeline. The collaboration is set to harness molecular, ...

With this new collaboration, Boehringer will have access to Tempus’ de-identified database containing molecular, clinical, and imaging data and its analytical platform, Lens. The aim is to ...

This partnership aims to integrate Tempus’s extensive de-identified database and analytical platform with Boehringer Ingelheim’s oncology pipeline. The collaboration is set to harness ...

CHICAGO, May 14, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration to advance Boehringer ...

Tempus AI Inc. TEM during the first quarter secured a multi-million dollar deal to build “the world’s largest foundation model for oncology.” “And this is big for a few reasons,” said ...